Lansoprazole Sun

Lansoprazole, the active ingredient in Lansoprazole Sun, is a proton pump inhibitor presented as an oral dosage form for systemic use. It reduces gastric acid production and is employed in the management of acid‑related gastrointestinal disorders such as gastro‑oesophageal reflux disease, peptic ulcer disease, and in regimens to eradicate Helicobacter pylori.

GNH USA supplies Lansoprazole Sun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑controlled manufacturing and reliable distribution across global markets, adhering to stringent regulatory standards and providing comprehensive support for product registration and logistics.

Lansoprazole acts on the gastric acid secretion pathway and is indicated for several acid‑related conditions. - Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of esophageal erosion. - Peptic ulcer disease: accelerates ulcer healing and reduces the risk of recurrence. - Helicobacter pylori eradication regimens: used as part of combination therapy to increase bacterial eradication rates.

Lansoprazole may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Headache: mild to moderate headache may occur. - Diarrhea: loose stools are reported. - Nausea: occasional nausea. - Abdominal discomfort: mild abdominal pain or bloating.

Serious or Rare Side Effects: - Severe allergic reaction: anaphylaxis or skin disorders such as Stevens‑Johnson syndrome. - Clostridioides difficile infection: risk of severe colitis. - Low magnesium levels: hypomagnesemia with prolonged use.

Before initiating therapy, consider the following precautions. - Assess renal function: adjust use in severe renal impairment. - Evaluate hepatic status: use with caution in moderate to severe liver disease. - Review long‑term need: prolonged therapy may increase risk of fractures and infections. - Monitor electrolytes: check magnesium and calcium levels during extended treatment. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture.

Lansoprazole can affect the plasma concentrations of several co‑administered drugs.

Major Interactions (Avoid): - Ketoconazole (and other antifungals requiring acidic pH): reduced absorption. - Atazanavir (and other protease inhibitors): decreased plasma concentrations.

Moderate Interactions (Monitor Closely): - Warfarin: may increase INR; monitor coagulation parameters. - Clopidogrel: reduced antiplatelet effect; monitor platelet function. - Digoxin: increased serum levels; monitor for signs of toxicity.